Journal of Clinical Endocrinology & Metabolism, Vol 81, 2613-2620, Copyright © 1996 by Endocrine Society

ARTICLES

Immunofunctional assay of human growth hormone (hGH) in serum: a possible consensus for quantitative hGH measurement

CJ Strasburger, Z Wu, CD Pflaum and RA Dressendorfer
Medical Clinic, Innenstadt University Hospital, Ludwig Maximilians University, Munich, Germany.

Confirmation of the diagnosis of GH deficiency in adults and children involves provocative testing for human (h) GH. Different commercially available immunoassays yield largely discrepant results in the measurement of GH levels in human serum. These discrepancies result in doubtful relevance of cut-off levels proposed for GH provocative testing. We have developed an immunofunctional assay method that allows quantitation of only those GH forms in circulation that possess both binding sites of the hormone for its receptor and thus can initiate a biological signal in target cells. An anti-hGH monoclonal antibody recognizing binding site 2 of hGH is immobilized and used to capture hGH from the serum sample. Biotin-labeled recombinant GH-binding protein in a second incubation step forms a complex with those hGH molecular isoforms that have both binding sites for the receptor. The signal is detected after a short third incubation step with labeled streptavidin. The assay is sensitive (detection range, 0.1-100 micrograms/L) and has average inter- and intraassay precisions of 10.3% and 7.3% respectively. Endogenous GH-binding protein does not interfere with the hGH result; placental lactogen slows no detectable cross- reaction in this immunofunctional assay. The degree of immunofunctionally active hGH forms in serum samples, calculated by comparison of immunofunctional assay and RIA results, varied between 52- 93%. We propose this immunofunctional assay for GH measurement as a new reference method for hGH quantitation in serum. The immunofunction assay translates only hGH forms into an assay signal that are capable of dimerizing GH receptors and, thus, of initiating a biological effect in target cells.

This article has been cited by other articles:

				B C Nindl and A. Fry Exercise modulation of growth hormone isoforms: current knowledge and future directions for the exercise endocrinologist * Commentary Br. J. Sports Med., June 1, 2007; 41(6): 346 - 348. [Full Text] [PDF]

				M. Bidlingmaier, J. Kim, C. Savoy, M. J. Kim, N. Ebrecht, S. de la Motte, and C. J. Strasburger Comparative Pharmacokinetics and Pharmacodynamics of a New Sustained-Release Growth Hormone (GH), LB03002, Versus Daily GH in Adults with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2926 - 2930. [Abstract] [Full Text] [PDF]

				S. Salemi, S. Yousefi, K. Baltensperger, I. C A F Robinson, A. Eble, D. Simon, P. Czernichow, G. Binder, E. Sonnet, and P. E Mullis Variability of isolated autosomal dominant GH deficiency (IGHD II): impact of the P89L GH mutation on clinical follow-up and GH secretion Eur. J. Endocrinol., December 1, 2005; 153(6): 791 - 802. [Abstract] [Full Text] [PDF]

				C. M. McHugh, R. T. Park, P. H. Sonksen, and R. I.G. Holt Challenges in Detecting the Abuse of Growth Hormone in Sport Clin. Chem., September 1, 2005; 51(9): 1587 - 1593. [Abstract] [Full Text] [PDF]

				A. Besson, S. Salemi, J. Deladoey, J.-M. Vuissoz, A. Eble, M. Bidlingmaier, S. Burgi, U. Honegger, C. Fluck, and P. E. Mullis Short Stature Caused by a Biologically Inactive Mutant Growth Hormone (GH-C53S) J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2493 - 2499. [Abstract] [Full Text] [PDF]

				Z. Wu, M. Bidlingmaier, S. C. Friess, S. E. Kirk, P. Buchinger, B. Schiessl, and C. J. Strasburger A New Nonisotopic, Highly Sensitive Assay for the Measurement of Human Placental Growth Hormone: Development and Clinical Implications J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 804 - 811. [Abstract] [Full Text] [PDF]

				W. C. Hymer, W. J. Kraemer, B. C. Nindl, J. O. Marx, D. E. Benson, J. R. Welsch, S. A. Mazzetti, J. S. Volek, and D. R. Deaver Characteristics of circulating growth hormone in women after acute heavy resistance exercise Am J Physiol Endocrinol Metab, October 1, 2001; 281(4): E878 - E887. [Abstract] [Full Text] [PDF]

				S. D. Anker, M. Volterrani, C.-D. Pflaum, C. J. Strasburger, K. J. Osterziel, W. Doehner, M. B. Ranke, P. A. Poole-Wilson, A. Giustina, R. Dietz, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone J. Am. Coll. Cardiol., August 1, 2001; 38(2): 443 - 452. [Abstract] [Full Text] [PDF]

				B. C. Nindl, W. C. Hymer, D. R. Deaver, and W. J. Kraemer Growth hormone pulsatility profile characteristics following acute heavy resistance exercise J Appl Physiol, July 1, 2001; 91(1): 163 - 172. [Abstract] [Full Text] [PDF]

				J. D. Wallace, R. C. Cuneo, M. Bidlingmaier, P. A. Lundberg, L. Carlsson, C. L. Boguszewski, J. Hay, M. Boroujerdi, A. Cittadini, R. Dall, et al. Changes in Non-22-Kilodalton (kDa) Isoforms of Growth Hormone (GH) after Administration of 22-kDa Recombinant Human GH in Trained Adult Males J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1731 - 1737. [Abstract] [Full Text]

				J. D. Wallace, R. C. Cuneo, M. Bidlingmaier, P. A. Lundberg, L. Carlsson, C. L. Boguszewski, J. Hay, M.-L. Healy, R. Napoli, R. Dall, et al. The Response of Molecular Isoforms of Growth Hormone to Acute Exercise in Trained Adult Males J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 200 - 206. [Abstract] [Full Text]

				M. Maccario, G. Aimaretti, G. Corneli, C. Gauna, S. Grottoli, M. Bidlingmaier, C. J. Strasburger, C. Dieguez, F. F. Casanueva, and E. Ghigo Short-term fasting abolishes the sex-related difference in GH and leptin secretion in humans Am J Physiol Endocrinol Metab, August 1, 2000; 279(2): E411 - E416. [Abstract] [Full Text] [PDF]

				F. Beuschlein, C. J. Strasburger, V. Siegerstetter, D. Moradpour, P. Lichter, M. Bidlingmaier, H. E. Blum, and M. Reincke Acromegaly Caused by Secretion of Growth Hormone by a Non-Hodgkin's Lymphoma N. Engl. J. Med., June 22, 2000; 342(25): 1871 - 1876. [Full Text] [PDF]

				C. J. Strasburger Methods in Determining Growth Hormone Concentrations: An Immunofunctional Assay Pediatrics, October 1, 1999; 104(4): 1024 - 1028. [Abstract] [Full Text]

				M. E. Wilson Effects of Estradiol and Exogenous Insulin-Like Growth Factor I (IGF-I) on the IGF-I Axis during Growth Hormone Inhibition and Antagonism J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4013 - 4021. [Abstract] [Full Text]

				A. Barreca, M. Bozzola, A. Cesarone, P. H. Steenbergh, P. E. Holthuizen, F. Severi, G. Giordano, and F. Minuto Short Stature Associated with High Circulating Insulin-Like Growth Factor (IGF)-Binding Protein-1 and Low Circulating IGF-II: Effect of Growth Hormone Therapy J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3534 - 3541. [Abstract] [Full Text]

				C. Jansson, C. Boguszewski, S. Rosberg, L. Carlsson, and K. Albertsson-Wikland Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein Clin. Chem., June 1, 1997; 43(6): 950 - 956. [Abstract] [Full Text] [PDF]

				A. Gertler, J. Grosclaude, C. J. Strasburger, S. Nir, and J. Djiane Real-time Kinetic Measurements of the Interactions between Lactogenic Hormones and Prolactin-Receptor Extracellular Domains from Several Species Support the Model of Hormone-induced Transient Receptor Dimerization J. Biol. Chem., October 4, 1996; 271(40): 24482 - 24491. [Abstract] [Full Text] [PDF]